Loading…
This event has ended. Visit the official site or create your own event on Sched.

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Trk 13: CER-Glob Health Econ [clear filter]
Tuesday, June 28
 

2:00pm

#246: Valuing the Signal and the Noise in Health Care Horizon Scanning
Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-574-L04-P; CME 1.25; IACET 1.25; RN 1.25

Horizon scanning is a method for identifying and monitoring interventions and innovations that have potential to impact clinical care, patient outcomes and the broader health care system. Dedicated horizon scanning programs focused on American and international markets function as publicly available tools useful for setting research agendas; planning regulatory and coverage/payment decisions; and providing early alerts to patients, clinicians, and health technology assessors. In this forum, representatives from American- and European-based horizon scanning efforts will demonstrate how both hits (early captured innovations with major impacts) and misses (e.g., non-identified interventions, non-impactful interventions), and the broader horizon scanning system methodology can provide a useful view of emerging technologies and the future health care landscape.

Learning Objectives

Identify horizon scanning resources and findings; Describe uses for horizon scanning findings by research funders, technology assessment organizations and coverage/payer groups; Describe the use of horizon scanning for understanding the larger landscape of innovation in a variety of clinical areas.

Chair

Christian Cuevas, PhD

Speaker

Horizon Scanning Systems: Comparison of US and International Systems
Diane Robertson

Panelist
Elise Berliner, PhD

Panelist
Christian Cuevas, PhD



Chair
avatar for Christian Cuevas

Christian Cuevas

Senior Clinical Analyst, Health Technology Assessment Group, ECRI Institute
Clinical Analyst at ECRI Institute I worked on the Horizon Scanning program following the clinical development of close to 200 emerging oncology interventions and determining their potential to have an impact on the healthcare system. Postdoctoral Fellow at University Pennsylvania... Read More →

Speakers
EB

Elise Berliner

Director, Technology Assessment Program, Agency For Healthcare Research and Quality (AHRQ)
Dr. Berliner is the Director of the Technology Assessment Program at the Agency for Healthcare Research and Quality (AHRQ). The Technology Assessment Program provides technology assessments to the Centers for Medicare & Medicaid Services (CMS) to inform Medicare coverage decisions... Read More →
avatar for Diane Robertson

Diane Robertson

Director, Health Technology Assessment, ECRI Institute
Served as ECRI Institute's project manager for the AHRQ Healthcare Horizon Scanning Program for 5 years. More than 30 years (including 22 with ECRI Institute’s Health Technology Assessment program) leading projects, health technology research and analysis, writing, and publishing... Read More →


Tuesday June 28, 2016 2:00pm - 3:15pm
103A Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
 
Wednesday, June 29
 

2:00pm

#348: Interpreting Meaningful Change on PROs: When to Talk, When to Use Cumulative Distribution Functions, and When to ROC
Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-572-L01-P; CME 1.25; IACET 1.25; RN 1.25

Methods to interpret the meaning of change in patient-reported outcome (PRO) scores often do not directly include perspectives of potential stakeholders. In this session, we will discuss how common and novel methods to define meaningful change can enhance insight into treatment benefit.

Learning Objectives

Distinguish when to use different methods to identify meaningful individual-level change and group-level differences on a patient-reported outcome; Recognize issues related to assessment frequency and missing data that impact the ability to assess treatment benefit.

Chair

Marian M Strazzeri, MS

Speaker

Panelist
Scott Komo, DrPH

Panelist
Cheryl D. Coon, PhD



Chair
avatar for Marian Strazzeri

Marian Strazzeri

Mathematical Statistician, OB, OTS, CDER, FDA
Marian Strazzeri currently works on clinical outcome assessments (COAs) and data standards within the Office of Biostatistics (OB) at FDA/CDER. Before joining FDA in her current capacity, she worked as a survey statistician at the National Center for Health Statistics (NCHS) in the... Read More →

Speakers
avatar for Cheryl Coon

Cheryl Coon

Principal, Outcometrix
Cheryl D. Coon, PhD is a psychometrician with over a decade of experience in the pharmaceutical field. She applies qualitative and quantitative methods to the development and evaluation of PRO instruments. During her years in the field, she has been involved in all stages of instrument... Read More →
SK

Scott Komo

Mathematical Statistician, Office of Translational Sciences, CDER, FDA
Scott Komo is a Senior Statistical Reviewer in the Office of Biostatistics, Center for Drug Evaluation and Research, FDA. He is involved with the design, analysis, and interpretation of studies that use clinical outcome assessments. He has supported multiple medical areas since joining... Read More →


Wednesday June 29, 2016 2:00pm - 3:15pm
107AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA

4:00pm

#370: Pricing, Patient Access, and What’s Next for Today’s Biopharma and Devices
Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-573-L04-P; CME 1.25; IACET 1.25; RN 1.25

Industry leaders, public payers, policy makers and issue experts provide insights into today’s heated debate about drug pricing, patient access and the policy battles ahead. This forum will offer engaging presentations, moderated discussion, and participant Q&A.

Learning Objectives

Identify key issues affecting the treatment pricing and patient access landscape; Describe how to apply potential models for determining a treatment’s value; Discuss ways to integrate new ideas for communicating a product’s rationale for patients, treaters and payers.

Chair

Jane Horvath, MHA

Speaker

Panelist
Matt Salo

Panelist
Michael Gray, MBA

Panelist
John Hoffman, MBA



Chair
avatar for Jane Horvath

Jane Horvath

Market Access Lead, 3D Communications
Jane Horvath, MHSA, leads 3D's Market Access and Value Communications team. Jane brings nearly 25 years of experience in health policy and reimbursement. She was Merck’s Executive Director of Health Policy and Reimbursement for a decade, Deputy Director of the RWJF project at Johns... Read More →

Speakers
avatar for Michael Gray

Michael Gray

Vice President and Chief Operating Officer, The Resource Group, Ascension
Michael has executive oversight and thought leadership responsibility for the ongoing development, implementation, and management of The Resource Group’s Strategic Direction. He spent seven years as President and CEO of Mercy Resource Management Inc., with responsibilities for Corporate... Read More →
avatar for John Hoffman

John Hoffman

Senior Director, Health Policy, Advocacy and Quality, Johnson & Johnson
As the Senior Director, Health Policy, Advocacy & Quality for the Strategic Customer Group at J&J North American Pharmaceuticals, John's responsibilities include ensuring unencumbered access to all J&J NA Pharma products for patients and physicians. The Strategic Customer Group develops... Read More →
avatar for Matt Salo

Matt Salo

Executive Director, National Association of Medicaid Directors
Matt Salo was named Executive Director of the National Association of Medicaid Directors in February 2011. The association represents all 56 of the nation’s state and territorial Medicaid Directors, and provides them with a strong unified voice in national discussions as well as... Read More →


Wednesday June 29, 2016 4:00pm - 5:15pm
107AB Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA